AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 292 min read$CYTK

Lee Sung sold $266K of CYTK

Lee Sung (EVP, Chief Financial Officer) sold 3,134 shares of CYTOKINETICS INC (CYTK) at $85.00 ($0.27M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lee Sung
Published Jun 29, 2026, 9:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

Confirms an open-market sale executed under a pre-arranged Rule 10b5-1 plan; typically limited incremental information for valuation.

02

Market read

Traders may monitor for patterns in insider activity, but this specific disclosure is unlikely to drive a major repricing by itself.

03

What to watch

The filing doesn’t disclose reasons for sale, and the post-transaction holdings (63,221 shares) may matter more than the single-day tranche size for interpreting insider behavior.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-06-29 (SEC Form 4)

Background

The article is an SEC Form 4 insider transaction by CYTOKINETICS CFO Lee Sung.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CFO Lee Sung filed a Form 4 selling 3,134 CYTK shares at $85 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this sale; any impact would be short-lived and sentiment-driven.

Evidence & confidence

The filing is a disclosed open-market sale with a pre-arranged 10b5-1 plan; such transactions are typically less informative than unscheduled sales.

Market effects

Sector

No sector read-through; this is company-specific insider transaction disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may reflect scheduled diversification rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.

Key entities

  • issuer
    CYTOKINETICS INC

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Lee Sung

    EVP, Chief Financial Officer who sold shares.

Read at source← All news

Related articles

AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup

SEC EDGAR 8-K6 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics Secures MHRA Marketing Authorization For MYQORZO In OHCM

Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).

rttnews.com4 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.

pharmaphorum.com4 min
JUL 24
$CYTKMed

What Makes Cytokinetics' MYQORZO Launch a Game Changer

Cytokinetics (CYTK) is commercializing MYQORZO (aficamten), approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The U.S. launch began in January 2026 and Europe is planned for Germany in Q2 2026. In 2025, revenue rose to $88.0M and net loss widened to $784.9M, while cash was about $1.22B.

kavout.com6 min
JUN 1
$CYTKMedAI 8/10

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics (Nasdaq: CYTK) said MYQORZO® (aficamten) has launched commercially in Germany, the first European availability, for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA II–III). The company cited EU approval in February 2026 based on SEQUOIA-HCM Phase 3 results, including a 1.76 mL/kg/min pVO2 improvement vs 0.0 with placebo over 24 weeks.

manilatimes.net4 min